Insights
Search Results
Client Highlights
11.17.25
Wilson Sonsini Advises onX on Strategic Investment from TCV
On November 3, 2025, onX, a pioneer in digital outdoor navigation and mapping software, announced a strategic investment from TCV, a leading growth equity firm known for supporting enduring consumer technology brands. The partnership brings additional operational expertise and long-term support as onX continues to scale its suite of adventure-specific navigation apps and redefine the outdoor experience. The company's existing investors, including Summit Partners, Madison Valley Partners, and onX founder Eric Siegfried, will remain active board members. Wilson Sonsini Goodrich & Rosati advised onX on the transaction.
Client Highlights
4.11.24
Wilson Sonsini Advises Boundless Bio on IP Matters Related to IPO
On March 27, 2024, Boundless Bio, a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share. All of the shares were offered by Boundless Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million. Boundless Bio’s common stock began trading on the Nasdaq Global Select Market on March 28, 2024, under the ticker symbol “BOLD," and closed on April 2, 2024. In addition, Boundless Bio has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Client Highlights
3.31.23
Firm Advises Cognito Therapeutics on $73 Million Series B Financing
On March 22, 2023, neurotechnology company Cognito Therapeutics announced a $73 million Series B financing round. The financing was led by FoundersX Ventures with participation from all its existing investors. The round also included support from new investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company. Wilson Sonsini Goodrich & Rosati advised Cognito on the transaction.
Client Highlights
11.09.22
Wilson Sonsini Advises Inscopix on Its Acquisition by Bruker
On November 8, 2022, Bruker Corporation, a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions, announced it acquired Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes. The miniscope technology was originally developed at Stanford University. Wilson Sonsini Goodrich & Rosati advised Inscopix on the transaction.
Client Highlights
1.27.22
Wilson Sonsini Advises SR One on Corporate, IP Matters Related to Simcha Therapeutics’ $40 Million Series B Financing
On January 27, 2022, Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40 million Series B financing. The round was led by SR One Capital Management and joined by other new investors including BVF Partners, Samsara BioCapital, Rock Springs Capital, ArrowMark Partners, and Logos Capital. Wilson Sonsini Goodrich & Rosati advised SR One on corporate and IP matters related to the transaction.